Opdivo fails to hit key target in small cell lung cancer study
admin 15th October 2018 Uncategorised 0Bristol-Myers Squibb’s immunotherapy Opdivo did not hit the primary target of a late-stage study testing its efficacy in certain patients with small cell lung cancer.
More: Opdivo fails to hit key target in small cell lung cancer study
Source: News